Kesimpta's complicated developmental path has shaped Genmab's approach to partnerships

Much can be learned from Kesimpta's path from disappointing cancer treatment to promising sclerosis medication, according to Genmab's CEO Jan van de Winkel – even if this has led to some frustration along the way.
Photo: Mik Eskestad/ERH
Photo: Mik Eskestad/ERH
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Having already received approvals in the US and Europe, Novartis is currently rolling out the sclerosis drug ofatumumab in what looks like it will be a highly successful year on the market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading